Product News

Share this article:

FDA OK'd a new indication for Eli Lilly's Symbyax, a Zyprexa and Prozac combination therapy. Symbyax is now indicated for patients with treatment-resistant depression, in addition to its prior indication for bipolar depression.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.